[{"orgOrder":0,"company":"Seoul National University Bundang Hospital","sponsor":"SK Chemicals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Cilostazol","moa":"Phosphodiesterase 3A","graph1":"Endocrinology","graph2":"Phase III","graph3":"Seoul National University Bundang Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Bundang Hospital \/ SK Chemicals","highestDevelopmentStatusID":"10","companyTruncated":"Seoul National University Bundang Hospital \/ SK Chemicals"}]

Find Endocrinology Clinical Drug Pipeline Developments & Deals for Cilostazol

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Seoul National University Bundang Hospital

                          Country arrow
                          ESCRS
                          Not Confirmed

                          Seoul National University Bundang Hospital

                          Country arrow
                          ESCRS
                          Not Confirmed

                          Details : Cilostazol is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 25, 2025

                          Lead Product(s) : Cilostazol

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : SK Chemicals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank